MedPath

A Study of Medical Records From Children With Central Precocious Puberty (CPP) in China

Recruiting
Conditions
Central Precocious Puberty
Registration Number
NCT05341128
Lead Sponsor
Takeda
Brief Summary

The main purpose is to describe how many children were treated during 24 months or less because of CPP and how treatment worked for them.

There are no participants in this trial, the study only involves reviewing participants medical past and current records and collecting information.

Detailed Description

This is an observational, non-interventional, retrospective study to evaluate the participants characteristics, current treatment patterns and resource usage in Chinese pediatric participants diagnosed with CPP.

This study will enroll approximately 1000 participants.

The data available in an existing data source the Chinese CPP Big Data Platform database will be analyzed. All the participants will be assigned to a single observational cohort:

• Pediatric Participants With CPP

This multi-center trial will be conducted in China. The overall duration of the study will be approximately 3 years.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1000
Inclusion Criteria

• Participants diagnosed with CPP and treated with GnRHa from the centers participating in this study within the Chinese CPP Big Data Platform database since 2015 to 2024.

CPP diagnosis is based on the clinical assessment and description by CPP specialized doctors.

Exclusion Criteria
  • Not received GnRHa as the treatment for CPP.
  • No available data for analysis.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percentage of Participants With CPP TreatmentUp to approximately 10 years
Secondary Outcome Measures
NameTimeMethod
Percentage of Participants With CPP Treatment at BaselineAt Baseline
Percentage of Participants With Luteinizing hormone (LH) SuppressionBaseline up to approximately 10 years
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Up to approximately 10 years

Trial Locations

Locations (5)

The Second Affiliated Hospital of Guangxi Medical University

🇨🇳

Nanning, Guangxi, China

Hainan Women and Children's Medical Center

🇨🇳

Haikou, Hainan, China

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

🇨🇳

Wuhan, Hubei, China

Shandong Provincial Hospital Affiliated to Shandong First Medical University

🇨🇳

Jinan, Shandong, China

Tianjin Medical University General Hospital

🇨🇳

Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath